KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Capital Expenditures (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of Capital Expenditures data on record, last reported at $35.6 million in Q3 2025.

  • For Q3 2025, Capital Expenditures changed N/A year-over-year to $35.6 million; the TTM value through Sep 2025 reached $210.0 million, changed N/A, while the annual FY2024 figure was $233.0 million, 26.86% down from the prior year.
  • Capital Expenditures reached $35.6 million in Q3 2025 per CRL's latest filing, down from $59.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $106.9 million in Q2 2023 and bottomed at -$58.0 million in Q4 2021.
  • Average Capital Expenditures over 5 years is $57.8 million, with a median of $62.6 million recorded in 2023.
  • Peak YoY movement for Capital Expenditures: skyrocketed 253.61% in 2022, then plummeted 41.4% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at -$58.0 million in 2021, then surged by 253.61% to $89.0 million in 2022, then dropped by 12.02% to $78.3 million in 2023, then dropped by 3.46% to $75.6 million in 2024, then plummeted by 52.95% to $35.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $35.6 million in Q3 2025, $59.3 million in Q1 2025, and $75.6 million in Q4 2024.